Oxytocin · cyclic nonapeptide · pharmacokinetics · research use only
Oxytocin half-life: one of the shortest clocks of any nasal peptide.
Oxytocin is a cyclic nine-residue peptide closed by a single disulfide bridge, and in circulation it is among the fastest-clearing compounds Titan stocks — plasma half-life is reported on the order of a few minutes. That short systemic clock is the defining variable for any research protocol: oxytocin behaves as an acute, single-window reagent rather than something that builds a steady level. This page explains why the clearance is so rapid, why the intranasal route is studied separately from systemic exposure, and what that means for COA identity on a disulfide-bridged peptide. It is a laboratory reference, not a human protocol or medical advice.
Minutes, not hours, in plasma
Circulating oxytocin is cleared rapidly — plasma half-life is reported on the order of a few minutes. Among Titan's nasal compounds it has one of the shortest systemic clocks. Practically, that means a research model treats exposure as a brief pulse: concentration rises and falls quickly rather than holding a plateau, so timing is everything and accumulation is not the design assumption.
How that shapes timing →A cyclic disulfide structure
Oxytocin is a nine-residue peptide whose ring is closed by a disulfide bond between two cysteines. That cyclic structure is part of its identity — and part of why a sequence-only COA is not enough. Enzymatic and reductive breakdown act on the linear chain and the bridge, which is why the compound is studied as a fast-clearing acute reagent rather than a slow-release one.
Why the bridge matters on a COA →Acute single-window, not accumulation
Because plasma exposure is short, research protocols model oxytocin around a single acute window timed to the experiment, not a multi-day build-up. This is the opposite design to a long-acting weekly peptide. The functional question in the literature is when the pulse lands relative to the measured outcome — the kinetics are read as one fast clock, not two.
Oxytocin vs PT-141 mechanisms →The intranasal route is studied separately
Whether and how much intranasally delivered oxytocin reaches central compartments is an open research question studied independently of systemic plasma levels — the nasal route is investigated precisely because the systemic clock is so short. Titan supplies a metered nasal spray, but the kinetic figures here describe the molecule, not a claim that any given fraction reaches any target.
Nasal peptide category →Identity, not just a purity number
A correct oxytocin COA confirms the nine-residue sequence and the intact disulfide bridge, not just a purity percentage — a reduced or mis-cyclised peptide is a different molecule with different behaviour. Titan's oxytocin nasal spray ships against an HPLC main-peak result with a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.
See the testing workflow →Research-use framing
Oxytocin is supplied strictly as a research-use-only reagent. The half-life figures here are reproduced as a laboratory reference for in-vitro and modelling work — not instructions for human use, and not a claim about any behavioural or physiological effect. Nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
One fast clock, read carefully.
Oxytocin's kinetics are unusual for how little they leave to interpret: clearance is fast and the design is acute. These are the figures a research protocol weighs, reproduced as a reference, not a human protocol.
- Compound
- Oxytocin — cyclic nine-residue peptide closed by a disulfide bridge.
- Plasma half-life
- Very short — reported on the order of a few minutes.
- Exposure profile
- Acute pulse — rises and falls quickly, no steady-state plateau.
- Resulting cadence
- Single timed window in research — not multi-day accumulation.
- Route note
- Intranasal central delivery studied separately from systemic plasma levels.
- Titan format
- Metered nasal spray, $74.99 — no reconstitution required.
Questions researchers ask
Before you order.
- What is the half-life of oxytocin?
- Oxytocin clears from plasma very quickly — its half-life in circulation is reported on the order of a few minutes, among the shortest of any peptide Titan stocks. That short systemic clock is the defining feature of its kinetics: it behaves as a brief acute pulse rather than a compound that builds and holds a level.
- Why does oxytocin clear so fast?
- It is a small cyclic nonapeptide subject to rapid enzymatic and reductive breakdown of both its chain and its disulfide bridge. Small peptides without stabilising modifications are generally cleared quickly, and oxytocin is a clear example — which is why research treats it as an acute single-window reagent.
- Does the nasal route change oxytocin's half-life?
- The intranasal route is studied separately from systemic plasma kinetics — it is investigated precisely because the systemic half-life is so short. How much intranasally delivered oxytocin reaches central compartments is an open research question, not a settled figure. The plasma half-life describes the molecule in circulation; the nasal route is a separate variable.
- Why does oxytocin identity matter more than a purity number?
- Because its structure is cyclic. A correct COA must confirm both the nine-residue sequence and the intact disulfide bridge — a reduced or mis-cyclised peptide is a different molecule. Titan's oxytocin ships with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.
- Is oxytocin approved for human use?
- Titan Peptide Lab supplies oxytocin strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. The kinetic figures on this page are a laboratory reference, not medical or dosing advice.